Clinical Trial Update: Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and tolerability of BIII 890 in patients with acute ischemic stroke has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• BIII 890

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Stroke | Phase 2 | Status: COMPLETED